IRCT20170430033730N6
Recruiting
未知
Evaluation of Clinical and Metabolic Responses to Combined Effect of Curcumin, Cholecalciferol, and Evening Primrose oil in Patients with Multiple Sclerosis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis.
- Sponsor
- Qazvin University of Medical Sciences
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with MS
Exclusion Criteria
- •Patients who do not want to cooperate;
- •Patients who have others complications such as: kidney disease? neuropathy and retinopathy;Patients with hypo and/or hyperthyroidism are excluded from this study.
- •Patients with other inflammatory conditions such as allergies and autoimmune diseases
- •pregnant women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Evaluation of the clinical and metabolic outcomes of pharmacotherapy based total parental nutrition support in adult patients undergoing bone marrow transplantatioParental nutrition support in bone marrow transplantation.Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedureIRCT201203041030N9Hematology-Oncology & SCT Research Center60
Not yet recruiting
Phase 2
A clinical trial to study the effects photodynamic therapy in patients with gum diseases.CTRI/2024/06/068905Shweta S Patil
Active, not recruiting
Phase 1
Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal JunctioEUCTR2014-000860-16-DETechnische Universität München Fakultaet fuer Medizin120
Recruiting
Phase 1
Study the effect of CAPRIDIN in the metabolic treatment of drug-resistant epilepsyIRCT20170315033086N11Shahid Beheshti University of Medical Sciences10
Active, not recruiting
Phase 1
Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso, a three-level, open-label, phase I-II studyAdenocarcinomas of the esophagus or gastro-esophageal junction and squamous cell carcinoma of the esophagus.MedDRA version: 20.0 Level: PT Classification code 10061534 Term: Oesophageal squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10030137 Term: Oesophageal adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000935-42-BEInstitut Jules Bordet100